Thus, regular brain imaging during crizotinib treatment may be considered and next generation ROS1 inhibitors are needed to manage or prevent intracranial progression for ROS1+NSCLC patients.24 In integrated analysis of STARTRK‐1/‐2 and ALKA‐372‐001, 23 ROS1+NSCLC patients with baseline BM were treated with next generation ROS1 inhibitor‐Entrectinib. Here, ROS1 is linked to non-small cell lung carcinoma.